96 related articles for article (PubMed ID: 28780131)
1. Commentary on: "Clonal evolution of chemotherapy-resistant urothelial carcinoma." Faltas BM, Prandi D, Tagawa ST, Molina AM, Nanus DM, Sternberg C, Rosenberg J, Mosquera JM, Robinson B, Elemento O, Sboner A, Beltran H, Demichelis F, Rubin MA.: Nat Genet. 2016 Oct 17. http://dx.doi.org/10.1038/ng.3692.
Lee BH
Urol Oncol; 2017 Sep; 35(9):577-578. PubMed ID: 28780131
[TBL] [Abstract][Full Text] [Related]
2. Clonal evolution of chemotherapy-resistant urothelial carcinoma.
Faltas BM; Prandi D; Tagawa ST; Molina AM; Nanus DM; Sternberg C; Rosenberg J; Mosquera JM; Robinson B; Elemento O; Sboner A; Beltran H; Demichelis F; Rubin MA
Nat Genet; 2016 Dec; 48(12):1490-1499. PubMed ID: 27749842
[TBL] [Abstract][Full Text] [Related]
3. Commentary on "Integrative clinical genomics of advanced prostate cancer". Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, Beltran H, Abida W, Bradley RK, Vinson J, Cao X, Vats P, Kunju LP, Hussain M, Feng FY, Tomlins SA, Cooney KA, Smith DC, Brennan C, Siddiqui J, Mehra R, Chen Y, Rathkopf DE, Morris MJ, Solomon SB, Durack JC, Reuter VE, Gopalan A, Gao J, Loda M, Lis RT, Bowden M, Balk SP, Gaviola G, Sougnez C, Gupta M, Yu EY, Mostaghel EA, Cheng HH, Mulcahy H, True LD, Plymate SR, Dvinge H, Ferraldeschi R, Flohr P, Miranda S, Zafeiriou Z, Tunariu N, Mateo J, Perez-Lopez R, Demichelis F, Robinson BD, Schiffman M, Nanus DM, Tagawa ST, Sigaras A, Eng KW, Elemento O, Sboner A, Heath EI, Scher HI, Pienta KJ, Kantoff P, de Bono JS, Rubin MA, Nelson PS, Garraway LA, Sawyers CL, Chinnaiyan AM.Cell. 21 May 2015;161(5):1215-1228.
Freedland SJ; Aronson WJ
Urol Oncol; 2017 Aug; 35(8):535. PubMed ID: 28623072
[TBL] [Abstract][Full Text] [Related]
4. Paired Exome Analysis Reveals Clonal Evolution and Potential Therapeutic Targets in Urothelial Carcinoma.
Lamy P; Nordentoft I; Birkenkamp-Demtröder K; Thomsen MB; Villesen P; Vang S; Hedegaard J; Borre M; Jensen JB; Høyer S; Pedersen JS; Ørntoft TF; Dyrskjøt L
Cancer Res; 2016 Oct; 76(19):5894-5906. PubMed ID: 27488526
[TBL] [Abstract][Full Text] [Related]
5. Spatial and temporal clonal evolution during development of metastatic urothelial carcinoma.
Thomsen MB; Nordentoft I; Lamy P; Høyer S; Vang S; Hedegaard J; Borre M; Jensen JB; Ørntoft TF; Dyrskjøt L
Mol Oncol; 2016 Nov; 10(9):1450-1460. PubMed ID: 27582092
[TBL] [Abstract][Full Text] [Related]
6. Clonal origin of lymph node metastases in bladder carcinoma.
Jones TD; Carr MD; Eble JN; Wang M; Lopez-Beltran A; Cheng L
Cancer; 2005 Nov; 104(9):1901-10. PubMed ID: 16196038
[TBL] [Abstract][Full Text] [Related]
7. Treatment resistance in urothelial carcinoma: an evolutionary perspective.
Vlachostergios PJ; Faltas BM
Nat Rev Clin Oncol; 2018 Aug; 15(8):495-509. PubMed ID: 29720713
[TBL] [Abstract][Full Text] [Related]
8. Commentary on "The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer." Chakravarty D, Sboner A, Nair SS, Giannopoulou E, Li R, Hennig S, Mosquera JM, Pauwels J, Park K, Kossai M, MacDonald TY, Fontugne J, Erho N, Vergara IA, Ghadessi M, Davicioni E, Jenkins RB, Palanisamy N, Chen Z, Nakagawa S, Hirose T, Bander NH, Beltran H, Fox AH, Elemento O, Rubin MA, University of Washington-Urology, Seattle, WA. Nat Commun 2014; 5:5383.
Lin D
Urol Oncol; 2016 Nov; 34(11):522. PubMed ID: 27814882
[No Abstract] [Full Text] [Related]
9. Mutational context and diverse clonal development in early and late bladder cancer.
Nordentoft I; Lamy P; Birkenkamp-Demtröder K; Shumansky K; Vang S; Hornshøj H; Juul M; Villesen P; Hedegaard J; Roth A; Thorsen K; Høyer S; Borre M; Reinert T; Fristrup N; Dyrskjøt L; Shah S; Pedersen JS; Ørntoft TF
Cell Rep; 2014 Jun; 7(5):1649-1663. PubMed ID: 24835989
[TBL] [Abstract][Full Text] [Related]
10. Re: Clonal Evolution of Chemotherapy-resistant Urothelial Carcinoma.
Black PC
Eur Urol; 2017 Oct; 72(4):653-654. PubMed ID: 28583313
[No Abstract] [Full Text] [Related]
11. Re: Clonal Evolution of Chemotherapy-resistant Urothelial Carcinoma.
Junker K; Ohlmann CH
Eur Urol; 2017 Aug; 72(2):316-317. PubMed ID: 28341322
[No Abstract] [Full Text] [Related]
12. Coexistent intraurothelial carcinoma and muscle-invasive urothelial carcinoma of the bladder: clonality and somatic down-regulation of DNA mismatch repair.
Blanes A; Rubio J; Sanchez-Carrillo JJ; Diaz-Cano SJ
Hum Pathol; 2009 Jul; 40(7):988-97. PubMed ID: 19368958
[TBL] [Abstract][Full Text] [Related]
13. Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma?
Gandour-Edwards R; Lara PN; Folkins AK; LaSalle JM; Beckett L; Li Y; Meyers FJ; DeVere-White R
Cancer; 2002 Sep; 95(5):1009-15. PubMed ID: 12209684
[TBL] [Abstract][Full Text] [Related]
14. Commentary on: "Inherited DNA-repair gene mutations in men with metastatic prostate cancer." Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R, Elemento O, Rubin MA, Robinson D, Lonigro R, Hussain M, Chinnaiyan A, Vinson J, Filipenko J, Garraway L, Taplin ME, AlDubayan S, Han GC, Beightol M, Morrissey C, Nghiem B, Cheng HH, Montgomery B, Walsh T, Casadei S, Berger M, Zhang L, Zehir A, Vijai J, Scher HI, Sawyers C, Schultz N, Kantoff PW, Solit D, Robson M, Van Allen EM, Offit K, de Bono J, Nelson PS. N Engl J Med. 2016 Aug 4;375(5):443-53.
Lee BH
Urol Oncol; 2017 Sep; 35(9):575-576. PubMed ID: 28789927
[TBL] [Abstract][Full Text] [Related]
15. Improved clonality analysis of multifocal bladder tumors by combination of histopathologic organ mapping, loss of heterozygosity, fluorescence in situ hybridization, and p53 analyses.
Denzinger S; Mohren K; Knuechel R; Wild PJ; Burger M; Wieland WF; Hartmann A; Stoehr R
Hum Pathol; 2006 Feb; 37(2):143-51. PubMed ID: 16426913
[TBL] [Abstract][Full Text] [Related]
16. H-RAS mutation is a key molecular feature of pediatric urothelial bladder cancer. A detailed report of three cases.
Castillo-Martin M; Collazo Lorduy A; Gladoun N; Hyun G; Cordon-Cardo C
J Pediatr Urol; 2016 Apr; 12(2):91.e1-7. PubMed ID: 26522772
[TBL] [Abstract][Full Text] [Related]
17. Excision repair cross-complementation group 1 (ERCC1) expression in advanced urothelial carcinoma patients receiving cisplatin-based chemotherapy.
Kim KH; Do IG; Kim HS; Chang MH; Kim HS; Jun HJ; Uhm J; Yi SY; Lim DH; Ji SH; Park MJ; Lee J; Park SH; Kwon GY; Lim HY
APMIS; 2010 Dec; 118(12):941-8. PubMed ID: 21091775
[TBL] [Abstract][Full Text] [Related]
18. Non-invasive papillary urothelial carcinoma of the vagina: molecular analysis of a rare case identifies clonal relationship to non-invasive urothelial carcinoma of the bladder.
Warzecha HN; Fend F; Steinhilber J; Abele H; Henes M; Harland N; Staebler A
Virchows Arch; 2017 Sep; 471(3):347-353. PubMed ID: 28589387
[TBL] [Abstract][Full Text] [Related]
19. [Surgical treatment of metastatic urothelial carcinoma of the bladder: Review of the Cancer Committee of the French Association of Urology].
Neuzillet Y; Larré S; Comperat E; Rouprêt M; Pignot G; Houede N; Quintens H; Wallerand H; Roy C; Soulie M; Pfister C;
Prog Urol; 2013 Oct; 23(12):951-7. PubMed ID: 24090779
[TBL] [Abstract][Full Text] [Related]
20. Comparative study of conventional urothelial carcinoma, squamous differentiation carcinoma and pure squamous carcinoma in patients with invasive bladder tumors.
Gluck G; Hortopan M; Stănculeanu D; Chiriță M; Stoica R; Sinescu I
J Med Life; 2014 Jun; 7(2):211-4. PubMed ID: 25408727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
